<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974970</url>
  </required_header>
  <id_info>
    <org_study_id>2018-02316</org_study_id>
    <nct_id>NCT04974970</nct_id>
  </id_info>
  <brief_title>Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy</brief_title>
  <official_title>Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the safety and efficacy of peanut immunotherapy in&#xD;
      children and adults with peanut allergy. Participants will receive immunotherapy with peanut&#xD;
      every 2 weeks for a period of 3 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Result (positive or negative) and cumulative reaction threshold at 3 months peanut oral food challenge (OFC).</measure>
    <time_frame>3 months</time_frame>
    <description>An unblinded evaluation of peanut OFC cumulative reaction threshold after 3 months of peanut immunotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum levels of allergen specific IgE and IgG4 after 6 weeks and 3 months of treatment compared to baseline peanut specific IgE and IgG4 after 3 months of treatment with peanut extract.</measure>
    <time_frame>3 months</time_frame>
    <description>An evaluation of changes in serum levels of allergen specific IgE and IgG4 after 6 weeks and 3 months of treatment compared to baseline peanut specific IgE and IgG4 after 3 months of treatment with peanut extract.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in titrated skin prick test after 6 weeks and 3 months of treatment with peanut extract compared to baseline.</measure>
    <time_frame>3 months</time_frame>
    <description>An evaluation of changes in titrated skin prick tests after 6 weeks and 3 months of treatment with peanut extract compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of treatment emergent adverse events during peanut immunotherapy</measure>
    <time_frame>3 months</time_frame>
    <description>An unblinded evaluation of the safety of peanut immunotherapy as measured by the incidence of treatment-emergent adverse events (AEs and SAEs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Food Allergy</condition>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Peanut allergenic extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injected peanut extract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peanut Immunotherapy</intervention_name>
    <description>Treatment will be injected peanut extract every 2 weeks for a period of 3 months.</description>
    <arm_group_label>Peanut allergenic extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed Consent as documented by signature.&#xD;
&#xD;
          2. Male or female subjects 12 to 45 years old at screening visit.&#xD;
&#xD;
          3. Patients with convincing history of IgE-mediated systemic allergic reaction after&#xD;
             consumption of peanut, and specific IgE above 95% positive predictive value:&#xD;
&#xD;
             a. Peanut ≥ 15kU/L or Ara h 2 ≥ 5U/L&#xD;
&#xD;
          4. Patients without a convincing history of IgE-mediated systemic allergic reaction (for&#xD;
             example only oral symptoms) after consumption of peanuts but with clear evidence of&#xD;
             sensitization (SPT &gt; 3 mm and/or positive specific IgE (&gt; 0.1kU/l) and a positive&#xD;
             standardized food challenge to peanut between V0 and V1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of severe anaphylaxis to the incriminated food with the&#xD;
             following symptoms: hypotension, hypoxia, neurological compromise (collapse, loss of&#xD;
             consciousness or incontinence).&#xD;
&#xD;
          2. Subjects with a history of systemic reaction to peanutskin prick test with commercial&#xD;
             extract.&#xD;
&#xD;
          3. Uncontrolled asthma (Forced expiratory volume at one second (FEV1) &lt;70% of predicted&#xD;
             value), active eosinophilic oesophagitis or any condition deemed incompatible by the&#xD;
             investigator.&#xD;
&#xD;
          4. Known or suspected systemic mastocytosis.&#xD;
&#xD;
          5. Subject currently under allergen immunotherapy.&#xD;
&#xD;
          6. Subject/parent with excessive anxiety unlikely to cope with study conditions as per&#xD;
             investigator's opinion.&#xD;
&#xD;
          7. Participation in a clinical study with a new investigational drug within the last 3&#xD;
             months or for a biological within the last 6 months prior to or during the study.&#xD;
&#xD;
          8. Use of immunosuppression or immunomodulatory drug (including anti-IgE or anti-Tumor&#xD;
             necrosis factor (TNF)) within 1 year prior to inclusion in study.&#xD;
&#xD;
          9. Relative counter-indication or inability to use epinephrine auto-injector.&#xD;
&#xD;
         10. Subjects receiving beta-blockers or angiotensin converting-enzyme (ACE) inhibitors.&#xD;
&#xD;
         11. Women who are pregnant or breast feeding.&#xD;
&#xD;
         12. Intention to become pregnant during the course of the study, or inadequate&#xD;
             contraceptive measures for women of child-bearing age (contraceptive measures&#xD;
             considered adequate are: intrauterine devices, hormonal contraceptives, such as&#xD;
             contraceptive pills, implants, transdermal patches, hormonal vaginal devices or&#xD;
             injections with prolonged release).&#xD;
&#xD;
         13. Other clinically significant concomitant disease states (e.g., renal failure, hepatic&#xD;
             dysfunction, cardiovascular disease, etc.).&#xD;
&#xD;
         14. Diseases with a contraindication for the use of adrenalin (e.g. hyperthyroidism,&#xD;
             glaucoma).&#xD;
&#xD;
         15. Known or suspected non-compliance, drug or alcohol abuse.&#xD;
&#xD;
         16. Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the participant.&#xD;
&#xD;
         17. Patients who are employees of the sponsor, institution or 1st grade relatives or&#xD;
             partners of the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christoph Caubet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christoph Caubet, MD</last_name>
    <phone>+41 79 553 40 85</phone>
    <email>Jean-Christoph.Caubet@hcuge.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François Graham, MD, MSc</last_name>
    <phone>15148908000</phone>
    <phone_ext>21534</phone_ext>
    <email>francois.graham.med@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pediatric allergy unit, Hôpitaux Universitaires de Genève (HUG)</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christoph Caubet, MD</last_name>
      <phone>+41 79 553 40 85</phone>
      <email>Jean-Christoph.Caubet@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Graham François, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Jean-Christoph Caubet</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

